Terminated PHASE3 INTERVENTIONAL 3-arm NCT03829657

Phase 3 Clinical Effect Durability of TD-9855 for Treating Symptomatic nOH in Subjects With Primary Autonomic Failure (REDWOOD)

A Phase 3, 22-week, Multi-center, Randomized Withdrawal Study of TD-9855 in Treating Symptomatic Neurogenic Orthostatic Hypotension in Subjects With Primary Autonomic Failure

Sponsor: Theravance Biopharma

Conditions MSA Parkinson's Disease (PD) Pure Autonomic Failure (PAF) Symptomatic Neurogenic Orthostatic Hypotension

Interventions Placebo ampreloxetine

Updated 22 times since 2019 Last updated: Dec 29, 2022 Started: Feb 22, 2019 Primary completion: Nov 10, 2021 Completion: Nov 10, 2021

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Stopped early due to company decision. Company decision based on analysis results in TD-9855-0169.

Other terminated trials from Theravance Biopharma

See all terminations from Theravance Biopharma

A PHASE3 clinical study on MSA and Parkinson's Disease (PD), this trial is terminated or withdrawn. The trial is conducted by Theravance Biopharma and has accumulated 22 data snapshots since 2019. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

22 versions recorded

Sep 2025 — Present [monthly]

Terminated PHASE3
Sep 2024 — Sep 2025 [monthly]

Terminated PHASE3
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE3
Feb 2023 — Jul 2024 [monthly]

Terminated PHASE3
Feb 2022 — Feb 2023 [monthly]

Terminated PHASE3

Status: Active Not Recruiting → Terminated

▶ Show 17 earlier versions

Nov 2021 — Feb 2022 [monthly]

Active Not Recruiting PHASE3

Status: Recruiting → Active Not Recruiting
Oct 2021 — Nov 2021 [monthly]

Recruiting PHASE3
Sep 2021 — Oct 2021 [monthly]

Recruiting PHASE3
Jun 2021 — Sep 2021 [monthly]

Recruiting PHASE3
Jan 2021 — Jun 2021 [monthly]

Recruiting PHASE3
Dec 2020 — Jan 2021 [monthly]

Recruiting PHASE3
Oct 2020 — Dec 2020 [monthly]

Recruiting PHASE3
Sep 2020 — Oct 2020 [monthly]

Recruiting PHASE3
Aug 2020 — Sep 2020 [monthly]

Recruiting PHASE3
Jul 2020 — Aug 2020 [monthly]

Recruiting PHASE3
May 2020 — Jul 2020 [monthly]

Recruiting PHASE3
Mar 2020 — May 2020 [monthly]

Recruiting PHASE3
Feb 2020 — Mar 2020 [monthly]

Recruiting PHASE3
Oct 2019 — Feb 2020 [monthly]

Recruiting PHASE3
Jul 2019 — Oct 2019 [monthly]

Recruiting PHASE3
Apr 2019 — Jul 2019 [monthly]

Recruiting PHASE3

Status: Not Yet Recruiting → Recruiting
Mar 2019 — Apr 2019 [monthly]

Not Yet Recruiting PHASE3

First recorded

Feb 2019

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Theravance Biopharma

Data source: Theravance Biopharma

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Barcelona, Spain , Berlin, Germany , Bilbao, Spain , Boca Raton, United States , Bologna, Italy , Budapest, Hungary , Calgary, Canada , Catania, Italy , Chicago, United States , Chieti, Italy and 61 more locations